Closing the gaps in treatment and management strategies in PAH


Journal Article

Pulmonary arterial hypertension (PAH ) is not typically diagnosed in a timely manner. It is now known that this condition affects all ages and genders and thus should be considered in patients with dyspnea, angina, fatigue, and syncope, particularly if they have other risk factors. There is no cure for PAH, but current approved treatment options that include prostanoids, endothelin-receptor antagonists, and phosphodiesterase type-5 inhibitors can greatly improve a patient's quality of life and may improve survival.

Duke Authors

Cited Authors

  • Krasuski, RA

Published Date

  • July 26, 2013

Published In

Volume / Issue

  • 16 / 2

Start / End Page

  • 9 - 13

International Standard Serial Number (ISSN)

  • 1094-1525

Citation Source

  • Scopus